Bahrami, Nazli
Jabeen, Shakila
Tahiri, Andliena
Sauer, Torill
Ødegård, Hilde Presterud
Geisler, Stephanie Beate
Gravdehaug, Berit
Reitsma, Laurens Cornelus
Selsås, Knut
Kristensen, Vessela
Geisler, Jürgen http://orcid.org/0000-0001-6239-3856
Funding for this research was provided by:
Helse Sør-Øst RHF (2017033)
Bodil and Magnus Cancer Research Fund, Oslo, Norway
Akershus University Hospital
Article History
Received: 23 September 2020
Accepted: 11 September 2021
First Online: 23 September 2021
Declarations
:
: JG has served on scientific advisory boards for AstraZeneca, Daiichi Sankyo, Eli Lilly, Novartis, Pierre Fabre, Pfizer and Roche. All other authors declare that they have no competing interests.
: The research protocol was evaluated and approved by the Regional Ethics Committee of South-East Norway (project number 2015-84). The biobank for the NEOLETEXE-trial was approved by the Regional Ethics Committee in Oslo, Norway and located and administered at the Akershus University Hospital, Lørenskog, Norway.
: All patients gave their written informed consent prior to participation in the trial.